No GIST-type c-kit gain of function mutations in neuroblastic tumours

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Neuroblastic tumours (NTs) show potential sensitivity to imatinib.
• Imatinib's mechanism may involve the c-kit receptor.
• Gastrointestinal stromal tumours (GISTs) are known to harbor c-kit mutations.

Purpose of the Study:

• To investigate the presence of GIST-type c-kit gene mutations in NTs.
• To identify NT subsets potentially responsive to imatinib therapy.
• To analyze mutations in c-kit exons 9, 11, 13, and 17.

Main Methods:

• Immunohistochemistry used to detect c-kit protein expression in 37 NTs.
• Denaturing high-performance liquid chromatography (HPLC) employed to detect c-kit gene mutations.
• Analysis focused on archival paraffin-embedded NT samples.

Main Results:

• No GIST-type c-kit gene mutations were identified in any of the 37 NTs.
• This finding applied to both c-kit positive (4 cases) and c-kit negative (33 cases) tumours.
• Denaturing HPLC analysis confirmed the absence of specific mutations.

Conclusions:

• c-kit receptor expression and GIST-type mutations are infrequent in NTs.
• Oncogenic c-kit activation in NTs likely differs from that in GISTs.
• The role of c-kit in NT pathogenesis and imatinib response requires further investigation.